SCHEMBL4123261

SCHEMBL4123261

COc1ccc2c(c1)CN(C(=O)C#Cc1cccc(Cl)c1)CC2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 3/20 0.47
ESR1 P03372 1/20 0.47
ESR2 Q92731 1/20 0.47
GRIN2C Q14957 4/20 0.46
TAS1R3 Q7RTX0 1/20 0.44
TAS1R1 Q7RTX1 1/20 0.44
TAS1R2 Q8TE23 1/20 0.44
CYP3A4 P08684 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
PDE4B Q07343 1/20 0.43
TSHR P16473 1/20 0.43
MEN1 O00255 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
KMT2A Q03164 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43
AKR1C3 P42330 1/20 0.43
ABHD6 Q9BV23 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4111406 0.96 ESR1 (0.52) GRM5ESR1ESR2GRIN2CTAS1R3
SCHEMBL4117529 0.88 PDE4B (0.55) NPC1PDE4BTSHRMEN1KMT2A
SCHEMBL4124858 0.86 GRM5 (0.46) GRM5CYP3A4NPC1RAB9APDE4B
SCHEMBL4118264 0.86 ESR2 (0.49) GRM5ESR1ESR2TAS1R3TAS1R1
SCHEMBL4112911 0.84 DRD3 (0.51) NPC1PDE4BMEN1KMT2A
SCHEMBL4113168 0.84 DRD3 (0.51) NPC1PDE4BMEN1KMT2A
SCHEMBL4111987 0.84 NPC1 (0.56) GRM5TAS1R3TAS1R1TAS1R2CYP3A4
SCHEMBL4113280 0.84 GRM5 (0.44) GRM5CYP3A4NPC1RAB9APDE4B
SCHEMBL4123561 0.84 ESR1 (0.57) ESR1ESR2TAS1R3TAS1R1TAS1R2
SCHEMBL4106020 0.84 NPC1 (0.58) GRM5TAS1R3TAS1R1TAS1R2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090075978-A1 SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS GRUNENTHAL GMBH (DE) 2009-03-19 US claimed
EP-1968938-A1 SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2008-09-17 EP claimed
WO-2007079957-A1 SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2007-07-19 WO claimed
US-20090075978-A1 SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS GRUNENTHAL GMBH (DE) 2009-03-19 US disclosed
US-20090075978-A1 SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS GRUNENTHAL GMBH (DE) 2009-03-19 US disclosed
EP-1968938-A1 SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2008-09-17 EP disclosed
WO-2007079957-A1 SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075978-A1 SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS PCCA, PPARA, PTGES GRM5 866/4885ESR1 2712/4885ESR2 1401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.